Skip to Main Content
Try STAT+ TODAY
Trending:
Health
Biotech
First Opinion
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Lipocine fatty liver drug study results don’t hold up to scrutiny

  • Adam Feuerstein

By Adam Feuerstein Jan. 17, 2019

Reprints

Red flags aplenty are sprouting from the clinical trial results disclosed by Lipocine (LPCN) on Thursday.

Lipocine’s stock price rose by nearly half after the small biotech issued a press release touting “meaningful” reductions in liver fat demonstrated by its experimental pill in a clinical trial. The data don’t hold up to scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Medicare Advantage insurers to repay billions under final federal…
Medicare Advantage insurers to repay billions under final federal audit rule
‘Everybody has blood on their hands’: A decade-long battle…
‘Everybody has blood on their hands’: A decade-long battle over Medicare Advantage audits is coming to…
Inside the fall of star MIT scientist David Sabatini
Inside the fall of star MIT scientist David Sabatini
Pharmalittle: Amgen pricing for Humira biosimilar may not help…
Pharmalittle: Amgen pricing for Humira biosimilar may not help patients; pharma wins court battle over drug…
Alphabet’s laid-off health tech employees on where their work…
Alphabet’s laid-off health tech employees on where their work heads next
FDA may not always require post-approval trials to be…
FDA may not always require post-approval trials to be enrolled before accelerated approvals

Recommended Stories